<p>RNS 编号：9091T Ondine Biomedical Inc.2026 年 2 月 20 日</p>
<p>TR-1：主要持股通知的标准表格</p>
<ol>
<li>发行人详情</li>
</ol>
<p>ISIN</p>
<p>CA68234M2058</p>
<p>发行人名称</p>
<p>ONDINE BIOMEDICAL INC</p>
<p>英国或非英国发行人</p>
<p>非英国</p>
<ol>
<li>通知原因</li>
</ol>
<p>其他</p>
<p>评论</p>
<p>根据章程的 1% 变动</p>
<ol>
<li>受通知义务的人的详细信息</li>
</ol>
<p>姓名</p>
<p>M&amp;G Plc</p>
<p>注册办公室所在城市（如适用）</p>
<p>伦敦</p>
<p>注册办公室所在国家（如适用）</p>
<p>英国</p>
<ol>
<li>股东的详细信息</li>
</ol>
<p>如果与上述受通知义务的个人不同，股东的全名</p>
<p>注册办公室所在城市（如适用）</p>
<p>注册办公室所在国家（如适用）</p>
<ol>
<li>超过或达到阈值的日期</li>
</ol>
<p>2026 年 2 月 11 日</p>
<ol>
<li>发行人通知的日期</li>
</ol>
<p>2026 年 2 月 12 日</p>
<ol>
<li>受通知义务的人的总持仓</li>
</ol>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>附加于股份的投票权百分比（8.A 总计）</td>
<td>通过金融工具的投票权百分比（8.B 1 + 8.B 2 总计）</td>
<td>两者总和的百分比（8.A + 8.B）</td>
<td>发行人持有的投票权总数</td>
</tr>
<tr>
<td>超过或达到阈值时的结果情况</td>
<td>13.041900</td>
<td>0.000000</td>
<td>13.041900</td>
<td>67604901</td>
</tr>
<tr>
<td>先前通知的持仓（如适用）</td>
<td>12.974380</td>
<td>0.000000</td>
<td>12.974380</td>
<td></td>
</tr>
</tbody>
</table>
<ol>
<li>超过或达到阈值时的结果情况的通知详情</li>
</ol>
<p>8A. 附加于股份的投票权</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>股份类别/类型 ISIN 代码（如可能）</td>
<td>直接投票权数量（DTR5.1）</td>
<td>间接投票权数量（DTR5.2.1）</td>
<td>直接投票权的百分比（DTR5.1）</td>
<td>间接投票权的百分比（DTR5.2.1）</td>
</tr>
<tr>
<td>CA68234M2058</td>
<td></td>
<td>67604901</td>
<td></td>
<td>13.041900</td>
</tr>
<tr>
<td>小计 8.A</td>
<td>67604901</td>
<td>13.041900%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>8B1. 根据 (DTR5.3.1R.(1) (a)) 的金融工具</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>金融工具类型</td>
<td>小计 8.B1</td>
</tr>
<tr>
<td>到期日期</td>
<td></td>
</tr>
<tr>
<td>行使/转换期限</td>
<td></td>
</tr>
<tr>
<td>如果行使/转换该工具可获得的投票权数量</td>
<td></td>
</tr>
<tr>
<td>投票权的百分比</td>
<td></td>
</tr>
</tbody>
</table>
<p>8B2. 根据 (DTR5.3.1R.(1) (b)) 具有类似经济效果的金融工具</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>金融工具类型</td>
<td>小计 8.B2</td>
</tr>
<tr>
<td>到期日期</td>
<td></td>
</tr>
<tr>
<td>行使/转换期限</td>
<td></td>
</tr>
<tr>
<td>实物或现金结算</td>
<td></td>
</tr>
<tr>
<td>投票权数量</td>
<td></td>
</tr>
<tr>
<td>投票权的百分比</td>
<td></td>
</tr>
</tbody>
</table>
<ol>
<li>关于受通知义务的人的信息</li>
</ol>
<ol>
<li>通过最终控制自然人或法律实体有效持有投票权和/或金融工具的控制企业的完整链条（如有必要请添加额外行）</li>
</ol>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>最终控制人</td>
<td>控制企业名称</td>
<td>如果等于或高于可通知阈值的投票权百分比</td>
<td>如果等于或高于可通知阈值的金融工具投票权百分比</td>
<td>如果等于或高于可通知阈值的两者总和</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Plc（母公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Regulated Entity Holding Company Limited（M&amp;G Plc 的全资子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Limited（M&amp;G Group Regulated Entity Holding Company Limited 的全资子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G FA Limited（M&amp;G Group Limited 的全资子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Investment Management Limited（M&amp;G FA Limited 的全资子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
</tbody>
</table>
<ol>
<li>在代理投票的情况下</li>
</ol>
<p>代理持有人姓名</p>
<p>持有的投票权数量和百分比</p>
<p>持有投票权的截止日期</p>
<ol>
<li>附加信息</li>
</ol>
<ol>
<li>完成日期</li>
</ol>
<p>2026 年 2 月 12 日</p>
<ol>
<li>完成地点</li>
</ol>
<p>伦敦，英国</p>
<p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并在我们的商业服务中以匿名方式与他人共享此分析。如需有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参见我们的隐私政策。结束 HOLPPUWWPUPQGMU</p>

OCEAW

OCEA

<p>M&G Plc 已通知其在 Ondine Biomedical Inc. 的持股变动，当前持股比例为 13.0419%，已超过 13% 的阈值。该变动于 2026 年 2 月 12 日报告，阈值在 2026 年 2 月 11 日达到。通知中包括 M&G Plc 及其子公司直接和间接持有的投票权的详细信息</p>

<p>RNS Number : 9091T Ondine Biomedical Inc. 20 February 2026</p>
<div class="lb-trans"><p>RNS 编号：9091T Ondine Biomedical Inc.2026 年 2 月 20 日</p>
</div><p>TR-1: Standard form for notification of major holdings</p>
<div class="lb-trans"><p>TR-1：主要持股通知的标准表格</p>
</div><p>1. Issuer Details</p>
<div class="lb-trans"><ol>
<li>发行人详情</li>
</ol>
</div><p>ISIN</p>
<div class="lb-trans"><p>ISIN</p>
</div><p>CA68234M2058</p>
<div class="lb-trans"><p>CA68234M2058</p>
</div><p>Issuer Name</p>
<div class="lb-trans"><p>发行人名称</p>
</div><p>ONDINE BIOMEDICAL INC</p>
<div class="lb-trans"><p>ONDINE BIOMEDICAL INC</p>
</div><p>UK or Non-UK Issuer</p>
<div class="lb-trans"><p>英国或非英国发行人</p>
</div><p>Non-UK</p>
<div class="lb-trans"><p>非英国</p>
</div><p>2. Reason for Notification</p>
<div class="lb-trans"><ol>
<li>通知原因</li>
</ol>
</div><p>Other</p>
<div class="lb-trans"><p>其他</p>
</div><p>Comments</p>
<div class="lb-trans"><p>评论</p>
</div><p>Movement of 1% as per Articles</p>
<div class="lb-trans"><p>根据章程的 1% 变动</p>
</div><p>3. Details of person subject to the notification obligation</p>
<div class="lb-trans"><ol>
<li>受通知义务的人的详细信息</li>
</ol>
</div><p>Name</p>
<div class="lb-trans"><p>姓名</p>
</div><p>M&amp;G Plc</p>
<div class="lb-trans"><p>M&amp;G Plc</p>
</div><p>City of registered office (if applicable)</p>
<div class="lb-trans"><p>注册办公室所在城市（如适用）</p>
</div><p>London</p>
<div class="lb-trans"><p>伦敦</p>
</div><p>Country of registered office (if applicable)</p>
<div class="lb-trans"><p>注册办公室所在国家（如适用）</p>
</div><p>United Kingdom</p>
<div class="lb-trans"><p>英国</p>
</div><p>4. Details of the shareholder</p>
<div class="lb-trans"><ol>
<li>股东的详细信息</li>
</ol>
</div><p>Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above</p>
<div class="lb-trans"><p>如果与上述受通知义务的个人不同，股东的全名</p>
</div><p>City of registered office (if applicable)</p>
<div class="lb-trans"><p>注册办公室所在城市（如适用）</p>
</div><p>Country of registered office (if applicable)</p>
<div class="lb-trans"><p>注册办公室所在国家（如适用）</p>
</div><p>5. Date on which the threshold was crossed or reached</p>
<div class="lb-trans"><ol>
<li>超过或达到阈值的日期</li>
</ol>
</div><p>11-Feb-2026</p>
<div class="lb-trans"><p>2026 年 2 月 11 日</p>
</div><p>6. Date on which Issuer notified</p>
<div class="lb-trans"><ol>
<li>发行人通知的日期</li>
</ol>
</div><p>12-Feb-2026</p>
<div class="lb-trans"><p>2026 年 2 月 12 日</p>
</div><p>7. Total positions of person(s) subject to the notification obligation</p>
<div class="lb-trans"><ol>
<li>受通知义务的人的总持仓</li>
</ol>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% of voting rights attached to shares (total of 8.A)</td>
<td>% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)</td>
<td>Total of both in % (8.A + 8.B)</td>
<td>Total number of voting rights held in issuer</td>
</tr>
<tr>
<td>Resulting situation on the date on which threshold was crossed or reached</td>
<td>13.041900</td>
<td>0.000000</td>
<td>13.041900</td>
<td>67604901</td>
</tr>
<tr>
<td>Position of previous notification (if applicable)</td>
<td>12.974380</td>
<td>0.000000</td>
<td>12.974380</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>附加于股份的投票权百分比（8.A 总计）</td>
<td>通过金融工具的投票权百分比（8.B 1 + 8.B 2 总计）</td>
<td>两者总和的百分比（8.A + 8.B）</td>
<td>发行人持有的投票权总数</td>
</tr>
<tr>
<td>超过或达到阈值时的结果情况</td>
<td>13.041900</td>
<td>0.000000</td>
<td>13.041900</td>
<td>67604901</td>
</tr>
<tr>
<td>先前通知的持仓（如适用）</td>
<td>12.974380</td>
<td>0.000000</td>
<td>12.974380</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>8. Notified details of the resulting situation on the date on which the threshold was crossed or reached</p>
<div class="lb-trans"><ol>
<li>超过或达到阈值时的结果情况的通知详情</li>
</ol>
</div><p>8A. Voting rights attached to shares</p>
<div class="lb-trans"><p>8A. 附加于股份的投票权</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class/Type of shares ISIN code(if possible)</td>
<td>Number of direct voting rights (DTR5.1)</td>
<td>Number of indirect voting rights (DTR5.2.1)</td>
<td>% of direct voting rights (DTR5.1)</td>
<td>% of indirect voting rights (DTR5.2.1)</td>
</tr>
<tr>
<td>CA68234M2058</td>
<td></td>
<td>67604901</td>
<td></td>
<td>13.041900</td>
</tr>
<tr>
<td>Sub Total 8.A</td>
<td>67604901</td>
<td>13.041900%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>股份类别/类型 ISIN 代码（如可能）</td>
<td>直接投票权数量（DTR5.1）</td>
<td>间接投票权数量（DTR5.2.1）</td>
<td>直接投票权的百分比（DTR5.1）</td>
<td>间接投票权的百分比（DTR5.2.1）</td>
</tr>
<tr>
<td>CA68234M2058</td>
<td></td>
<td>67604901</td>
<td></td>
<td>13.041900</td>
</tr>
<tr>
<td>小计 8.A</td>
<td>67604901</td>
<td>13.041900%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))</p>
<div class="lb-trans"><p>8B1. 根据 (DTR5.3.1R.(1) (a)) 的金融工具</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of financial instrument</td>
<td>Sub Total 8.B1</td>
</tr>
<tr>
<td>Expiration date</td>
<td></td>
</tr>
<tr>
<td>Exercise/conversion period</td>
<td></td>
</tr>
<tr>
<td>Number of voting rights that may be acquired if the instrument is exercised/converted</td>
<td></td>
</tr>
<tr>
<td>% of voting rights</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>金融工具类型</td>
<td>小计 8.B1</td>
</tr>
<tr>
<td>到期日期</td>
<td></td>
</tr>
<tr>
<td>行使/转换期限</td>
<td></td>
</tr>
<tr>
<td>如果行使/转换该工具可获得的投票权数量</td>
<td></td>
</tr>
<tr>
<td>投票权的百分比</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))</p>
<div class="lb-trans"><p>8B2. 根据 (DTR5.3.1R.(1) (b)) 具有类似经济效果的金融工具</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of financial instrument</td>
<td>Sub Total 8.B2</td>
</tr>
<tr>
<td>Expiration date</td>
<td></td>
</tr>
<tr>
<td>Exercise/conversion period</td>
<td></td>
</tr>
<tr>
<td>Physical or cash settlement</td>
<td></td>
</tr>
<tr>
<td>Number of voting rights</td>
<td></td>
</tr>
<tr>
<td>% of voting rights</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>金融工具类型</td>
<td>小计 8.B2</td>
</tr>
<tr>
<td>到期日期</td>
<td></td>
</tr>
<tr>
<td>行使/转换期限</td>
<td></td>
</tr>
<tr>
<td>实物或现金结算</td>
<td></td>
</tr>
<tr>
<td>投票权数量</td>
<td></td>
</tr>
<tr>
<td>投票权的百分比</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>9. Information in relation to the person subject to the notification obligation</p>
<div class="lb-trans"><ol>
<li>关于受通知义务的人的信息</li>
</ol>
</div><p>2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)</p>
<div class="lb-trans"><ol>
<li>通过最终控制自然人或法律实体有效持有投票权和/或金融工具的控制企业的完整链条（如有必要请添加额外行）</li>
</ol>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultimate controlling person</td>
<td>Name of controlled undertaking</td>
<td>% of voting rights if it equals or is higher than the notifiable threshold</td>
<td>% of voting rights through financial instruments if it equals or is higher than the notifiable threshold</td>
<td>Total of both if it equals or is higher than the notifiable threshold</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Plc (Parent company)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Regulated Entity Holding Company Limited (wholly owned subsidiary of M&amp;G Plc)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Limited (wholly owned subsidiary of M&amp;G Group Regulated Entity Holding Company Limited)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G FA Limited (wholly owned subsidiary of M&amp;G Group Limited)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Investment Management Limited (wholly owned subsidiary of M&amp;G FA Limited)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>最终控制人</td>
<td>控制企业名称</td>
<td>如果等于或高于可通知阈值的投票权百分比</td>
<td>如果等于或高于可通知阈值的金融工具投票权百分比</td>
<td>如果等于或高于可通知阈值的两者总和</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Plc（母公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Regulated Entity Holding Company Limited（M&amp;G Plc 的全资子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Limited（M&amp;G Group Regulated Entity Holding Company Limited 的全资子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G FA Limited（M&amp;G Group Limited 的全资子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Investment Management Limited（M&amp;G FA Limited 的全资子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
</tbody>
</table>
</div><p>10. In case of proxy voting</p>
<div class="lb-trans"><ol>
<li>在代理投票的情况下</li>
</ol>
</div><p>Name of the proxy holder</p>
<div class="lb-trans"><p>代理持有人姓名</p>
</div><p>The number and % of voting rights held</p>
<div class="lb-trans"><p>持有的投票权数量和百分比</p>
</div><p>The date until which the voting rights will be held</p>
<div class="lb-trans"><p>持有投票权的截止日期</p>
</div><p>11. Additional Information</p>
<div class="lb-trans"><ol>
<li>附加信息</li>
</ol>
</div><p>12. Date of Completion</p>
<div class="lb-trans"><ol>
<li>完成日期</li>
</ol>
</div><p>12-Feb-2026</p>
<div class="lb-trans"><p>2026 年 2 月 12 日</p>
</div><p>13. Place Of Completion</p>
<div class="lb-trans"><ol>
<li>完成地点</li>
</ol>
</div><p>London, United Kingdom</p>
<div class="lb-trans"><p>伦敦，英国</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END HOLPPUWWPUPQGMU</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并在我们的商业服务中以匿名方式与他人共享此分析。如需有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参见我们的隐私政策。结束 HOLPPUWWPUPQGMU</p>
</div>

REG - Ondine Biomedical M&G PLC - 公司持股情况